Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold? (Q34800447)

4 August 2017

1 reference

title

Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold? (English)

1 reference

4 August 2017

1 reference

Stuart C Apfel

1

1 reference

4 August 2017

1 January 2002

1 reference

International Review of Neurobiology

4 August 2017

1 reference

4 August 2017

50

1 reference

4 August 2017

393-413

1 reference

The role of endogenous nerve growth factor in human diabetic neuropathy

4 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950083-0

7 January 2021

Nerve growth factor administration protects against experimental diabetic sensory neuropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950083-0

7 January 2021

Nerve growth factor prevents experimental cisplatin neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950083-0

7 January 2021

Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950083-0

7 January 2021

Nerve growth factor prevents toxic neuropathy in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950083-0

7 January 2021

Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial. rhNGF Clinical Investigator Group

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950083-0

7 January 2021

A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950083-0

7 January 2021

Topical treatment with nerve growth factor for neurotrophic keratitis

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950083-0

7 January 2021

Diabetic neuropathy, nerve growth factor and other neurotrophic factors

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950083-0

7 January 2021

GDNF is an age-specific survival factor for sensory and autonomic neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950083-0

7 January 2021

Activation of the sphingomyelin cycle through the low-affinity neurotrophin receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950083-0

7 January 2021

Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950083-0

7 January 2021

Variables influencing neuropathic endpoints: the Rochester Diabetic Neuropathy Study of Healthy Subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950083-0

7 January 2021

Peripheral neuropathy in transgenic diabetic mice: restoration of C-fiber function with human recombinant nerve growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950083-0

7 January 2021

Deficits in sciatic nerve neuropeptide content coincide with a reduction in target tissue nerve growth factor messenger RNA in streptozotocin-diabetic rats: effects of insulin treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950083-0

7 January 2021

Human recombinant nerve growth factor replaces deficient neurotrophic support in the diabetic rat

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950083-0

7 January 2021

Nerve growth factor prevents neurotoxic effects of cisplatin, vincristine and taxol, on adult rat sympathetic ganglion explants in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950083-0

7 January 2021

Endogenous levels of nerve growth factor (NGF) are altered in experimental diabetes mellitus: a possible role for NGF in the pathogenesis of diabetic neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950083-0

7 January 2021

Axonal transport of endogenous nerve growth factor (NGF) and NGF receptor in experimental diabetic neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950083-0

7 January 2021

GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950083-0

7 January 2021

Retrograde axonal transport of transmitter enzymes, fucose-labeled protein, and nerve growth factor in streptozotocin-diabetic rats

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950083-0

7 January 2021

Destruction of the sympathetic nervous system in neonatal rats and hamsters by vinblastine: prevention by concomitant administration of nerve growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950083-0

7 January 2021

The trk proto-oncogene encodes a receptor for nerve growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950083-0

7 January 2021

The trkB tyrosine protein kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950083-0

7 January 2021

Reversal by NGF of cytostatic drug-induced reduction of neurite outgrowth in rat dorsal root ganglia in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950083-0

7 January 2021

trkC, a new member of the trk family of tyrosine protein kinases, is a receptor for neurotrophin-3

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950083-0

7 January 2021

Topical treatment with nerve growth factor for corneal neurotrophic ulcers

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950083-0

7 January 2021

A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS Clinical Trials Group Team 291

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950083-0

7 January 2021

Low contents of nerve growth factor in serum and submaxillary gland of diabetic mice. A possible etiological element of diabetic neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950083-0

7 January 2021

The effect of systemically administered recombinant human nerve growth factor in healthy human subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950083-0

7 January 2021

Nerve Growth Factor Attenuates Neurotoxic Effects of Taxol on Spinal Cord-Ganglion Explants from Fetal Mice

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950083-0

7 January 2021

Nerve growth factor alleviates a painful peripheral neuropathy in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950083-0

7 January 2021

A vitamin D(3) derivative (CB1093) induces nerve growth factor and prevents neurotrophic deficits in streptozotocin-diabetic rats

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950083-0

7 January 2021

Clenbuterol stimulates neurotrophic support in streptozotocin-diabetic rats

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950083-0

7 January 2021

Effect of NGF and anti-NGF on neuropathic pain in rats following chronic constriction injury of the sciatic nerve

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950083-0

7 January 2021

Effect of NGF and neurotrophin-3 treatment on experimental diabetic autonomic neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2950083-0

7 January 2021

10.1016/S0074-7742(02)50083-0

Identifiers

DOI

1 reference

4 August 2017

1 reference

PubMed ID

12198818